Characteristic Signs on T2*-Based Imaging and Their Relationship with Results of Reperfusion Therapy for Acute Ischemic Stroke: A Systematic Review and Evidence to Date.
10.5469/neuroint.2018.01039
- Author:
Hak Cheol KO
1
;
Chang Woo RYU
;
Seong Jong YUN
;
Jun Seok KOH
;
Hee Sup SHIN
;
Eui Jong KIM
Author Information
1. Department of Neurosurgery, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Meta-Analysis ; Original Article
- Keywords:
Susceptibility vessel sign;
Prominent hypointense vessel sign;
T2*-based MRI;
Acute ischemic stroke;
Reperfusion
- MeSH:
Arteries;
Humans;
Magnetic Resonance Imaging;
Odds Ratio;
Reperfusion*;
Stroke*;
Thrombectomy
- From:Neurointervention
2018;13(2):90-99
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Characteristic signs – the susceptibility vessel sign (SVS) and the prominent hypointense vessel sign (PHVS) – on T2*-based magnetic resonance imaging (T2*MRI) can be seen for acute ischemic stroke with large artery occlusion. In this study, we investigated the evidence to support our hypothesis that these findings may help to predict outcomes after reperfusion therapy. MATERIALS AND METHODS: We searched for papers describing SVS and PHVS in patients treated with reperfusion therapy for acute ischemic stroke, and their functional/radiologic outcomes were systematically reviewed. RESULTS: Nine studies on the SVS and six studies on the PHVS were included. The pooled odds ratio (OR) of recanalization after intravenous thrombolysis or mechanical thrombectomy was not significantly different with the presence of SVS (OR, 0.615; 95% confidence interval [CI], 0.335–1.131 and OR, 0.993; 95% CI, 0.629–1.567). The OR of favorable functional outcome after reperfusion therapy in terms of the presence of PHVS varied (0.083 to 1.831) by study. CONCLUSION: Our meta-analysis of the published data showed that a SVS was not a predictive factor for recanalization after reperfusion therapy for acute ischemic stroke. Currently, the data available on T2*MRI are too limited to warrant reperfusion therapy in routine practice. More data are needed from studies with randomized treatment allocation to determine the role of T2*MRI.
